Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2026)

Royalty Pharma has reported Other Accumulated Expenses for 7 years, with the latest figure at $17.5 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 6.02% year-over-year to $17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.5 million (down 6.02% YoY) and the FY2025 annual result came in at $53.2 million, down 22.5% from the prior year.
• Other Accumulated Expenses retreated to $17.5 million in Q1 2026 per RPRX's latest filing, from $53.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $97.5 million in Q2 2024 and troughed at $3.1 million in Q2 2025.
• A 5-year average of $29.6 million and a median of $17.5 million in 2026 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses surged 503.08% in 2024, then plunged 96.85% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $12.4 million in 2022, then fell by 8.27% to $11.4 million in 2023, then soared by 503.08% to $68.6 million in 2024, then decreased by 22.5% to $53.2 million in 2025, then tumbled by 67.12% to $17.5 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $17.5 million, $53.2 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.